Key facts
- This page summarizes PERCEPTIVE ADVISORS LLC's Form 3 filing for Yarrow Bioscience, Inc. (VYNE).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 29 Jul 2026, 16:11.
PERCEPTIVE ADVISORS LLC - 27 Jul 2026 Form 3 Insider Report for Yarrow Bioscience, Inc. (VYNE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- VYNE
- Reported as of
- 27 Jul 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 29 Jul 2026, 16:11:39 UTC
- Prior SEC filing
- 22 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
PERCEPTIVE ADVISORS LLC filed Form 3 for Yarrow Bioscience, Inc. (VYNE) on 29 Jul 2026.
Change
- Previous filing in this sequence was filed on 22 Jul 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (3)
CIK 0001224962
Primary reporting owner
PERCEPTIVE ADVISORS LLC
- Relationship
- 10%+ Owner
- Address
- 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
- Signature
- /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
- Signature date
- 29 Jul 2026
CIK 0001249675
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
- Relationship
- 10%+ Owner
- Address
- 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
- Signature
- /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
- Signature date
- 29 Jul 2026
CIK 0001164426
EDELMAN JOSEPH
- Relationship
- 10%+ Owner
- Address
- 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
- Signature
- /s/ Joseph Edelman
- Signature date
- 29 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VYNE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 266,309
- Date
- 27 Jul 2026
- Ownership
- See Footnote
- Footnotes
- F1
VYNE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 266,309
- Date
- 27 Jul 2026
- Ownership
- See Footnote
- Footnotes
- F1
VYNE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 266,309
- Date
- 27 Jul 2026
- Ownership
- See Footnote
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VYNE
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Jul 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 967,360
- Exercise price
- $0.000100
- Footnotes
- F1, F2
VYNE
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Jul 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 967,360
- Exercise price
- $0.000100
- Footnotes
- F1, F2
VYNE
holding
Derivative
Pre-Funded Warrant (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 Jul 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 967,360
- Exercise price
- $0.000100
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman ("Mr. Edelman") serves as the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of their indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor or Mr. Edelman is a beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Footnote F2
The Pre-Funded Warrants are immediately exercisable and do not expire. The terms of the Pre-Funded Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund (as defined herein) to exercise any of its Warrants.